The new arm of NCI-MATCH — a sweeping precision oncology umbrella trial comprising over three dozen cohorts of patients matched to treatment based on the molecular characteristics of their cancers — will evaluate whether patients with dMMR and LAG-3 expression can benefit from combination treatment with nivolumab and relatlimab.

The trial will continue enrolling patients whose cancers harbor BRAF mutations to Arm H, which is evaluating treatment with dabrafenib and trametinib. Results from this arm previously showed that the targeted therapy combination led to responses across multiple BRAF-mutated cancer types. Now, the researchers aim to confirm their findings by enrolling additional patients.